Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 1:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Weight Loss, Obesity, Childhood, Obesity
Interventions
Lomaira 8Mg Tablet
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
12 Months to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Loma Linda, California
Conditions
Obesity
Interventions
VI-0521, Placebo matched phentermine/topiramate
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
5
States / cities
San Diego, California • Ridgefield, Connecticut • Durham, North Carolina + 2 more
Conditions
Obesity, Phentermine Withdrawal
Interventions
Abrupt cessation of phentermine pharmacotherapy
Drug
Lead sponsor
Center for Weight Management, California
Other
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Roseville, California • Sacramento, California
Conditions
Acute Lymphoblastic Leukemia in Remission, Hodgkin Lymphoma in Remission, Non-Hodgkin Lymphoma in Remission, Cancer Survivorship
Interventions
Phentermine/Topiramate ER, Health Behavior and Lifestyle Counseling
Drug · Behavioral
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
12 Years to 24 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Memphis, Tennessee
Active, not recruiting Early Phase 1 Interventional Results available

Phentermine/Topiramate in Adolescents With Type 2 Diabetes and Obesity

NCT04881799
Conditions
Pediatric Obesity
Interventions
Phentermine/Topiramate (Qsymia), Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 20 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Active, not recruiting No phase listed Observational

Anti-obesity Pharmacotherapy and Inflammation

NCT05756764
Conditions
Obesity
Interventions
Semaglutide, Phentermine-Topiramate combination, Phentermine, Tirzepatide, Topiramate, Diethylpropion, Naltrexone/Bupropion, Liraglutide
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
35 Years to 60 Years
Enrollment
30 participants
Timeline
2023 – 2026
U.S. locations
2
States / cities
New Orleans, Louisiana
Conditions
Overweight, Obesity
Interventions
pramlintide acetate, sibutramine, phentermine, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 13 more
Conditions
Overweight, Obesity
Interventions
VI-0521, Placebo, Alcohol, alcohol placebo
Drug · Other
Lead sponsor
VIVUS LLC
Industry
Eligibility
21 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Lincoln, Nebraska
Recruiting Not applicable Interventional Accepts healthy volunteers

Preoperative Weight Loss for Open Abdominal Wall Reconstruction

NCT05925959
Conditions
Abdominal Wall Hernia
Interventions
Preoperative Weight Management Program
Other
Lead sponsor
Benjamin T. Miller
Other
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Cleveland, Ohio
Conditions
Hypothalamic Obesity, Hypothalamic Tumor, Craniopharyngioma
Interventions
Phentermine / Topiramate Extended Release Oral Capsule [Qsymia], Placebo
Drug · Other
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
6 Years to 28 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Seattle, Washington
Conditions
Obesity
Interventions
Phentermine Pill, Orforglipron
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Boston, Massachusetts
Active, not recruiting No phase listed Observational

Weight Loss Management in Endometrial Cancer Survivors

NCT06877572
Conditions
Endometrial Cancer Survivors, Weight Management, Early Stage Endometrial Cancer
Interventions
Weight loss with pharmacotherapy, Weight loss without pharmacotherapy
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Obesity
Interventions
Phentermine-Topiramate, Meal Replacement Therapy, Placebo
Drug · Dietary Supplement · Other
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Obesity, Morbid, Bariatric Surgery, Adolescent, Young Adult, Drug Therapy
Interventions
Phentermine, Immediate Release Topiramate, Placebo for Phentermine, Placebo for Immediate Release Topiramate
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 24 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Renal Impairment
Interventions
Topirmate and Phentermine
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
19 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
Anaheim, California • Miami, Florida • Orlando, Florida + 1 more
Conditions
Blood Pressure
Interventions
VI-0521, Phentermine, Placebo
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
28
States / cities
Anniston, Alabama • Mobile, Alabama • Lincoln, California + 25 more
Conditions
Diabetes
Interventions
Phentermine/Topiramate, Placebo
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more
Conditions
Childhood Obesity
Interventions
Phentermine, Placebo
Drug
Lead sponsor
Russell McCulloh, MD
Network
Eligibility
12 Years to 17 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Baton Rouge, Louisiana • Kansas City, Missouri • Lebanon, New Hampshire + 3 more
Completed Not applicable Interventional

Preventing Diabetes

NCT05395377
Conditions
PreDiabetes
Interventions
Registered Dietitian/Nutritionist, Diabetes Prevention Program, Weight Watchers, Reimagined, DPP or RDN Counseling + Medication, Bariatric Surgery Evaluation
Behavioral · Other
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years to 89 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Danville, Pennsylvania
Conditions
Adolescent Obesity
Interventions
Lifestyle Modification Therapy (LSMT), Phentermine Pill, Topiramate Pill, Placebo
Behavioral · Drug
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 17 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Obesity, Type 2 Diabetes
Interventions
VI-0521
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
2,487 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Birmingham, Alabama • Ridgefield, Connecticut • New York, New York + 3 more
Conditions
Obesity
Interventions
Semaglutide, Orlistat, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Loma Linda, California
Conditions
Hepatic Impairment
Interventions
Phentermine and Topiramate
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Abuse Potential of Istradefylline

NCT02609477
Conditions
Drug Abuse
Interventions
Istradefylline, Phentermine 45 mg, Placebo
Drug · Other
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Salt Lake City, Utah